Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Inclusion Criteria: Subjects must meet all of the following criteria * Subjects volunteer to participate in the study and agree to sign the informed consent with good compliance and follow-up. * Subjects are 18 years old or older when signing the informed consent and gender is not limited. * Subjects were diagnosed with advanced hepatobiliary malignant tumors (clinical stage IV) by imaging and histological examination, including hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, gallbladder carcinoma and mixed carcinoma. * The disease is not suitable for radical surgery and/or topical treatment, or disease progression occurs after surgery and/or local treatment. * At least one measurable lesion (according to RECIST version 1.1): the measurable lesion has a long diameter ≥ 10 mm or lymphadenopathy has a short diameter ≥ 15 mm in spiral CT scan. * Patients fail after at least one systemic failure, including surgery, intervention, radiotherapy, chemotherapy and targeted therapy and require palliative treatment. Definition of treatment failure: Disease progression during treatment or relapse after treatment, such as after at least once radical or palliative resection surgery, revenue recurrence or progression after intervention therapy or radiotherapy. Intervention therapy or oxaliplatin treatment must be more than 1 cycle, and molecular targeted therapy must more than ≥14 days. Definition of intolerance: Grade ≥IV hematologic toxicity, or grade ≥III non- hemat…